Navigation Links
Atlantis SR Plus Catheter

ProductsAtlantis SR Plus Catheter
Company Boston Scientific Corporation
Item Atlantis SR Plus Catheter
Features 
  • Outstanding Crossability: Tapered tip; Lower distal shaft diameter; Minimal entry profile.
  • Image Clarity; high definition 40Mhz IVUS catheter.
  • 6F Guide Catheter Compatibility.
    • Description This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary interventional procedures.
    Info Boston Scientific Corporation
    Customer Service: (888) 272-1001
    Web site: http://www.bostonscientific.com

    Related medicine products :

    1. Atlantis Anterior Cervical Plate System
    2. Atlantis SR Pro Coronary Imaging Catheter
    3. Lumboperitoneal Catheter and Shunt Systems
    4. Bactiseal EVD Catheter
    5. Maverick Over-The-Wire 9 mm Catheter
    6. Maverick Over-The-Wire 12 mm Catheter
    7. Maverick Over-The-Wire 15 mm Catheter
    8. Maverick Over-The-Wire 20 mm Catheter
    9. Maverick Over-The-Wire 25 mm Catheter
    10. Maverick Over-The-Wire 30 mm Catheter
    11. Trak Back II Catheter Pull-Back Device
    ...r transfusion needs. A recognized leader in autotr...ay to add the safety of microfiltration for a vari...ve or postoperative applications, autologous or ho...rovides both convenience and versatility in the re...
    This high technology cast plaster cutter saw is very easy and comfortable to use.
    Designed to reduce noise to a minimum results in less emotional trauma for patients and less hearing trauma for the clinician. The innovative motor plus saw design delivers high power in a smaller, l
    The True/Fix Cannulated Bone Screw System contains 7.0mm large cannulated bone screws and 3.5mm cortical and 4.0mm cannulated cancellous bone screws.
    Medicine Products:
    (Date:5/22/2008)... in progression of risk factors as subjects aged ,...New insights into lung disease and lung function i..., The researchers analyzed data from the U.S. Nat...oronary Artery Risk Development in Young Adults) o...ears of health assessments in more than 5,000 youn...
    (Date:5/22/2008)...illion Americans whove received drug-eluting stent...right future, according to new research from the U...The findings, among the first large follow-up stud...uting stents compared to bare metal stents, will b...the American College of Cardiology. Patients with ...
    (Date:5/22/2008)...ozed at wheel; National Road Safety Fou...W YORK, May 22 /PRNewswire/ -- As people jam the r...hich marks the start of the peak summer,driving se...into -- a,drowsy driver, says the National Road Sa...vides free driver safety films and programs includ...
    (Date:5/22/2008)...ewswire/ -- Many baby boomers,incorrectly believe ...to a,new survey conducted by Harris Interactive(R)...IP). Most say that disability insurance is importa...ey do not have any disability,income protection., ...830/AHIPLOGO ), "Baby boomers recognize the valu...
    Breaking Medicine News(10 mins):Health News:CARDIA Studies Open Window on Heart, Lung Diseases 2Health News:CARDIA Studies Open Window on Heart, Lung Diseases 3Health News:More patients with drug-coated cardiac stents survive, avoid costly follow-up procedures 2Health News:Drowsy Driving as Dangerous as Drunk Driving 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 2Health News:Many Baby Boomers Incorrectly Believe They Are Protected Against the Risk of Disability 3
    ... labeling has been introduced in Canada for most p...ontribute towards the good health of Canadians in ... from partial hydrogenation, which is an industria...le oils and extends their shelf life in addition t...
    ... U.S. Congress called on Monday for more rigorous ...nts.// The Food and Drug Administration (FDA) has...ng -- but significant gaps remain, according to Re... Democrat on the House Appropriations subcommittee...
    ...deal with a nearly certain outbreak of a bird flu ...ys a top EU medical expert.// Professor Johan Gi...on and Control (ECDC) was speaking after chief vet...25 EU nations met to discuss protecting European w...
    ... scientists has sparked new fears over the safety ...hey should eat no more than two portions a year.//... New York State University, concluded that the hea...tish fish are outweighed by risks caused by pollut...
    Other Medicine News:Health News:Scrutiny Sought For Reused Devices in U.S. 2Health News:EU medical chief says Europe ready for bird flu 2Health News:Salmon's own diet sure to affect yours 2
    (Date:5/22/2008)...didate, RDEA806, Demonstrated No Reproductive Toxi... -, - RDEA427 Selected as Clinical Candidate, Demo...ential for Once Daily Oral Dosing -, SAN DIEGO, M... Inc.,(Nasdaq: RDEA ) today announced preclinical...tase inhibitor (NNRTI) candidate, RDEA806, demonst...
    (Date:5/21/2008)...derscore the Utility of CAPHOSOL in Treating Oral ...- New data show that CAPHOSOL(R), (http://www.caph...eves painful oral,mucositis (OM) and improves qual...erapy and radiation therapy. These data were repor... 33rd Annual Congress of the,Oncology Nursing Soci...
    (Date:5/21/2008)...nted at 12th World Congress on the Menopause show ...yspareunia, two of the most frequent s... ARBOR, Mich., May 21 /- QuatRx Pharm...rom a pivotal Phase 3 study of Ophena(TM),(ospemif...mptoms of,vulvovaginal atrophy, a common condition...
    (Date:5/21/2008)...EIGHTS, N.J., May 21 /- Gen...ed that multiple abstracts,featuring its lead onco...meeting of the American Society of Clinical Oncolo...he abstracts include the following:, -- Initial ... G4544, an oral gallium-containing Compound. ...
    Breaking Medicine Technology:Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 2Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 3Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 2CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 3CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 4CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 5CAPHOSOL(R) Relieves Oral Mucositis (OM) and Improves Quality-of-Life in Cancer Patients Receiving Chemoradiation 6QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 2QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy 3Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 2Genta Clinical Programs Featured in Multiple Abstracts at the Annual Meeting of the American Society of Clinical Oncology 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 1FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 2FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 3FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 4FDA Approves Additional Dosage Strengths of Shires ADHD Treatment VYVANSE 28TM 29 28lisdexamfetamine dimesylate 29 Which May Help Physicians Tailor T 2429 5QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 1QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 2QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena 28TM 29 28ospemifene 29 to Treat Postmenopausal Vaginal Syndrome 1131 3Hookah Smoking as Tough on Lungs as Cigarettes 9019 1Hookah Smoking as Tough on Lungs as Cigarettes 9019 2Hookah Smoking as Tough on Lungs as Cigarettes 9019 3Novel anticancer strategy moves from laboratory to clinic 9014 1Novel anticancer strategy moves from laboratory to clinic 9014 2Novel anticancer strategy moves from laboratory to clinic 9014 3
    ...in Key Lung Compartments, REINACH and BASEL, Switz...rpida Ltd. today announced promising,results of "f...led,Human Microdose studies included a total of 19...udy is the first ever using Microdosing,for the de...ments.,The results showed that AR-709 achieves hig...
    ...Mar 29, 2007 - ACADIA Pharmaceuticals,Inc. (Nasdaq...ovative technology to fuel drug discovery and clin...ervous system,disorders, today announced that the ...gress on Schizophrenia Research, held from,March 2...rado.,Presentations will cover ACADIA,s two schizo...
    Other Medicine Technology:Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 2Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 3Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 4Arpida Announces Promising Results of "First-In-Man" Studies With,AR-709 5ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5